Clinical trials
T-cell Malignancies clinical trials
Below are recruiting t-cell malignancies clinical trials, each written for real people, not researchers. We’re tracking 279 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05911217RecruitingPhase 1
CT041 treatment after chemotherapy for resected pancreatic cancer
This Phase 1 study tests whether CT041 is safe and may help prevent pancreatic cancer from coming back after it’s been removed and you’ve completed standard chemotherapy. You may be eligible if your tumor is positive for CLDN18.2 and your recovery and blood tests meet key requirements.
Beijing, Beijing MunicipalityAges 18–79 - NCT06066346RecruitingPhase 2
Talquetamab for multiple myeloma after CAR T-cell therapy
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
Basking Ridge, New JerseyAges 18 years+ - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06505369RecruitingPhase 2
Immune therapy for newly diagnosed multiple myeloma before stem cell transplant
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
CopenhagenAges 18–70 - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06614686RecruitingPhase 1
CAR-T therapy for advanced head and neck cancer
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
ShanghaiAges 18–70 - NCT06623396RecruitingPhase 1
CAR T-cell therapy for stomach and esophagus cancer
This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT06648889RecruitingPhase 2
Isatuximab for CD38 positive T-cell ALL
This trial tests if the drug isatuximab can help adults with a type of T-cell leukemia (T-ALL) that has come back or hasn't fully responded to treatment, or has minimal remaining disease after chemotherapy. The treatment targets a protein called CD38 found on the leukemia cells.
AugsburgAges 18 years+ - NCT06799247RecruitingPhase 3
Investigating Descartes-08 for myasthenia gravis
This trial tests an experimental therapy called Descartes-08, made from your own immune cells, to see if it can improve muscle weakness in people with generalized myasthenia gravis. The therapy is designed to target and reduce harmful antibodies that cause the condition.
Tucson, ArizonaAges 18 years+ - NCT06855823RecruitingPhase 1/Phase 2
Study of golidocitinib plus pomalidomide for relapsed/refractory PTCL
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–80 - NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+ - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Basking Ridge, New JerseyAges 18 years+ - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT02532452RecruitingPhase 2
T-cells made to fight a specific virus
This Phase 2 study gives you special “virus-targeting” immune cells (T-cells) to help your body control a current viral infection or virus that has come back (reactivated). It may help reduce the virus activity while you are immunocompromised, meaning your immune system is weaker than usual.
Akron, OhioAges 2 days+ - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years - NCT05952804RecruitingPhase 2
IVIG to help prevent infections after CAR-T treatment
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
Duarte, CaliforniaAges 18 years+
Hear when a new T-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t-cell malignancies?
- Yes. Clin2 currently lists 279 recruiting t-cell malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.